TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07229742: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2173 Injection in Patients With Active Lupus Nephritis

Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 51 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT07229742 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07229742 Rescue Dossier →